Patents by Inventor Xianzhi Mao

Xianzhi Mao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF
    Publication number: 20180044669
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: October 26, 2017
    Publication date: February 15, 2018
    Inventors: Sudhir AGRAWAL, Wayne JIANG, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • Compositions for inhibiting checkpoint gene expression and uses thereof
    Patent number: 9828601
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: November 28, 2017
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Wayne Jiang, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF
    Publication number: 20160251652
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: February 25, 2016
    Publication date: September 1, 2016
    Inventors: Sudhir Agrawal, Wayne Jiang, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • Human receptor tyrosine kinase, KDR
    Patent number: 6841367
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Human receptor tyrosine kinase, KDR
    Patent number: 6841382
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • In vivo methods of determining activity of receptor-type kinase inhibitors
    Publication number: 20040101478
    Abstract: In vivo methods are disclosed for measuring compound inhibition of kinase receptor activity. Examples are provided which show a direct correlation between in vivo inhibition of KDR kinase inhibition and circulating blood and plasma levels of the inhibitor. These data are used to predict and validate non-quantifable in vitro measurements, such as murine endothelial cell IC50 values. The in vivo potency of a compound determined by an assay of the present invention may be utilized to select dose amounts and frequencies for further preclinical animal model studies and human clinical studies designed to generate safety, potency and efficacy profiles for the respective inhibitor.
    Type: Application
    Filed: September 29, 2003
    Publication date: May 27, 2004
    Inventors: Kenneth A Thomas, Xianzhi Mao, Richard L Kendall
  • Human receptor tyrosine kinase, KDR
    Publication number: 20030055239
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Application
    Filed: March 18, 2002
    Publication date: March 20, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Human receptor tyrosine kinase, KDR
    Publication number: 20030032160
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Application
    Filed: December 18, 2001
    Publication date: February 13, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Human receptor tyrosine kinase, KDR
    Patent number: 6359115
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Xianzhi Mao, Kenneth A. Thomas, Andrew Tebben
  • Human receptor tyrosine kinase, KDR
    Patent number: 6204011
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: June 17, 1998
    Date of Patent: March 20, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Xianzhi Mao, Kenneth A. Thomas, Andrew Tebben